中文产业新闻精选评分48Chinese source
艾伯维JUVO™（Tavapadon）获FDA批准上市，系全球首个帕金森病选择性D1/D5受体激动剂
获FDA批准全球首个帕金森靶向药上市
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
获FDA批准全球首个帕金森靶向药上市
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.